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A clinicopathological study of asymptomatic gastric cancer
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Summary The clinicopathological profiles of 419 patients with asymptomatic gastric cancer (AGC) first
detected by gastric screening, were reviewed and compared with those of the 1727 patients with symptomatic
gastric cancer (SGC). The incidence of AGC increased gradually and has amounted to 30% of the total
resected cases in recent years. About 75% ofAGC cases were ofearly cancer and 84% were negative for lymph
node metastases. In contrast, only 33% of SGC cases were of early cancer and 57% were node positive.
Curative resection was done in 97% ofAGC and 75% of SGC. The cumulative 5 and 10 year survival rates of
patients with curatively resected AGC were 85.2% and 72.2%, respectively, while those for patients with SGC
were 66.8% and 55.4%. These data demonstrated that most patients with asymptomatic gastric cancers could
expect a curative resection, i.e. have a better clinical outcome, than those with symptomatic cancer.
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Gastric cancer has been the most common malignancy and
the leading cause of cancer death in Japan for a long time
(Yamagata and Hisamichi, 1979). Recently, the incidence of
gastric cancer has gradually declined. The mortality as a
result of tumours, however has decreased even more
markedly (Kampschoer et al., 1989). Improvements in
dealing with gastric cancer have led to this success, which
is considered to be the result of two factors. One is the
advances in the treatment of gastric cancer involving surgical
resection with systemic lymph node dissection, which have
been widely practised in Japan (Okamura et al, 1988).
Another, probably more important and evident factor, is
the increase in the incidence of early gastric cancer (Green et
al., 1988). In Japan, a gastric screening test is conducted on a
national scale as mass screening in communities or group
screening performed at the request of companies or
affiliations. Besides such organised screening, individual
screening is also commonly done as one of the examinations
of a voluntary general checkup (Kampschoer et al., 1989).
The screening programme usually consists of, first, a double-
contrast barium meal study for detecting any gastric
abnormalities, and subsequent close examination by endo-
scopy for confirming the presence and, further, the nature of
the gastric lesions by endoscopical biopsy. In some cases,
especially in individual screening, endoscopical examination is
done first without preceding barium meal study. The subject
of screening is not only a person with any upper abdominal
symptoms but also one without symptoms. Many asympto-
matic gastric cancers have been detected at these screenings.
Because the progression of cancer is related to time, cancer
detected in the preclinical, that is asymptomatic, period can
be expected to carry a better prognosis that that detected
with symptoms (Eddy, 1983; Hisamichi and Sugawara, 1984).
In the current study, we attempted to clarify the
clinicopathological characteristics of asymptomatic gastric
cancer (AGC) detected by a gastric screening test in
comparison with symptomatic gastric cancer (SGC) treated
in the same period.
Materials and methods
A total of 2146 patients underwent gastrectomy for primary
gastric cancer in the Department of Gastroenterological
Surgery, National Kyushu Cancer Center between 1972 and
1991. Many of them were the residents of Fukuoka city and
some were those of other cities of Fukuoka prefecture or
those of other prefectures in Kyushu. Most of the patients
were diagnosed as having gastric cancer at other screening
institutions or clinics and visited for operative treatment, and
some were firstly diagnosed at our hospital. Of these, 1727
cases were patients with symptomatic gastric cancer and the
remaining 419 patients had no gastric symptoms at the time
of their visit. These latter 419 patients had been pointed out
as having asymptomatic gastric cancer (AGC) by the gastric
screening test. The 419 patients with AGC were thus included
as the materials of this study and the 1727 patients with SGC
treated in the same period were used for clinical and
pathological control. All available data including patient's
sex and age, tumour location and size, macroscopical
appearance, depth of gastric wall invasion, degree of
histological differentiation, histological lymph node metas-
tases, pathological stage of the disease, operative curability
and patient's survival were compared. All pathological data
were extracted by review of their case notes. Whenever
multiple cancers were found in a stomach, the largest ones
were used for the evaluations.
Early gastric cancer was defined as cancer confined either
to the mucosa or to the mucosa and submucosa, regardless of
the status of lymph node metastases, while advanced gastric
cancer was deemed as that invading into or through the
proper muscle layer. The macroscopical appearance, the level
of lymph node metastases and pathological stage of the
disease were classified according to the General Rules for
Gastric Cancer Study in Surgery and Pathology in Japan
(Japanese Research Society for Gastric Cancer, 1981). The
advanced tumours were divided macroscopically into type 1,
fungating; type 2, ulcerating circumscribed; type 3, ulcerating
infiltrative; type 4, diffusely infiltrative and type 5,
unclassified type. Type 5 included advanced cancer, macro-
scopically resembling the early type (Mori et al., 1990). Type
0 included all early cancers. The histological types were
divided into differentiated and undifferentiated types. The
level of lymph node metastases was classified from NO to N4
according to the presence and extent of nodal involvement.
Previous episodes of gastric screening within the last 5
years were checked and the correlation between screening
interval and pathological stage of the disease at operation
was investigated. The survival statuses were obtained for
many of the patients from the follow-up charts of the
outpatients clinic and some by telephone contact with the
patients or their immediate family. Statistical analyses of the
clinicopathological factors were performed by the chi-square
test and Student's t-test, while the survival rates were
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constructed with the method of Kaplan and Meier, and the
generalised Wilcoxon test was used for the analysis of
significance. The level of significance was P<0.05.
Results
Table I shows the incidence of AGC among all the resected
gastric cancers for each 5 year period of the study. The
incidence of AGC increased gradually and has amounted to
about 30% in recent years. The clinical and pathological data
Table I Time trends for the presence of symptoms in resected
gastric cancer cases during the following four 5 year periods (%)
No. of cases Asymptomatic Symptomatic
1972-76 361 29 (8.0) 332 (92.0)
1977-81 580 72 (12.4) 508 (87.6)
1982-86 629 143 (22.7) 486 (77.3)
1987-91 576 175 (30.4) 401 (69.6)
Total 2146 419 (19.5) 1727 (80.5)
of 419 AGC and 1727 SGC are listed in Table II. They
consisted of 312 men (74.5%) and 107 women (25.5%) with a
mean age of 61.1 years in the AGC group and 1090 men
(63.1%) and 637 women (36.9%) with a mean age of 59.6
years in the SGC group. Statistically significant differences
were observed in the male/female ratio and the mean age
(P<0.01). Symptoms of symptomatic cases were various and
the most common complaint was epigastric pain found in 887
cases (51.4%). Other symptoms were loss of appetite (221
cases, 12.8%), nausea or vomiting (108, 6.3%), weight loss
(93, 5.4%) and haemorrhage (haematemesis and/or melena)
(59, 3.4%). The mean tumour maximum diameter was
smaller in AGC and, as for the gross appearance of
advanced cancer, localised tumour (type 1 or 2) was more
prevalent in AGC than infiltrative tumour (type 3 or 4)
compared with SGC (P<0.01). Type 4 cancer was rare in
AGC.
The important and notable differences between AGC and
SGC were found in depth of gastric wall invasion and lymph
node metastases. About 75% (315/419) of AGC were early
cancer and, further nearly half (196/419) of AGC were
mucosal cancer. On the other hand, only 33% (563/1727) of
SGC were early cancer. Lymph node metastases were found
in 16% (66/419) or AGC and 57% (977/1727) of SGC; a
significant difference was recognised between the two.
Table II Clinicopathological data of 419 AGC and 1727 SGC cases
AGC SGC P-
(n=419) (n= 1727) value
Mean age (years) 61.1+ 10.7 59.6+ 12.3 <0.01
Sex
Male
Female
Operative curability
Curative
Non-curative
Tumour location
Upper
Middle
Lower
Whole stomach
Tumour maximum diameter
(mean+s.d.) (cm)
Macroscopic appearance
Type 0
Type 1
Type 2
Type 3
Type 4
Type 5
Histological type
Differentiated
Undifferentiated
Depth of invasion
Intramucosa
Submucosa
Proper muscle
Subserosal
Serosal
Lymph node metastases
NO
NI
N2
N3,4
Unknown
Pathological stage
Stage I
Stage II
Stage III
Stage IV
312 (74.5)
107 (25.5)
407 (97.1)
12 (2.9)
67 (16.0)
156 (37.2)
192 (45.8)
4 (1.0)
3.25+2.46
315 (75.2)
13 (3.1)
26 (6.2)
20 (4.8)
4 (1.0)
41 (9.8)
317 (75.7)
102 (24.3)
196 (46.8)
119 (28.4)
39 (9.3)
24 (5.7)
41 (9.8)
353 (84.2)
39 (9.3)
21 (5.0)
6 (1.4)
0
336 (80.2)
35 (8.4)
39 (9.3)
9 (2.1)
1090 (63.1)
637 (36.9)
1289 (74.6)
438 (25.4)
267 (15.5)
500 (29.0)
771 (44.6)
189 (10.9)
6.29+2.97
563 (32.6)
30 (1.7)
286 (16.6)
446 (25.8)
190 (11.0)
212 (12.3)
976 (56.5)
751 (43.5)
272 (15.7)
291 (16.9)
132 (7.6)
225 (13.0)
807 (46.7)
745 (43.1)
330 (19.1)
470 (27.2)
177 (10.2)
5 (0.3)
625 (36.2)
153 (8.9)
479 (27.2)
470 (27.2)
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01
<0.01 I I I I
$0
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Concerning the histological type of cancer, the differentiated
type was more prevalent in AGC compared with SGC
(P<0.01).
A total of 457 among the 1727 cases of SGC had
undergone gastric screening within 5 years before their
presentation with symptoms, and 440 of them were judged
as negative for malignancy (25.5% of SGC). The remaining
17 cases did not undergo the recommended close examination
after the initial screening and the compliance rate was 96.3%.
Of the 440 cases, 337 (76.6%) were screened with barium
meal study, 54 (12.3%) with endoscopy and the remaining 49
(11.1%) with both. Nearly half of these cases (210/440)
underwent screening within a year. Only 56 cases of SGC
(3.2%), however, had regularly undergone annual screening.
Of the 419 with AGC, 196 were either diagnosed on first
screening or had not been screened in the 5 years before the
screening at which the gastric tumour was detected, and the
other 223 had been screened within the previous 5 years. Of
the latter cases, 220 were judged to be negative for
malignancy at the previous screenings (52.5% of AGC).
The remaining three cases dropped out and the compliance
rate was 98.7%. Of the 220 cases, 161 (73.2%) underwent
screening within a year and a total of 145 cases of AGC
(34.6%) had regularly undergone annual screening, 27 were
screened between 1 and 2 years ago, 16 between 2 and 3 years
ago, nine between 3 and 4 years ago and seven between 4 and
5 years previously. Of the 220 screened cases, 167 (75.9%)
wee screened with a barium meal study, 30 (13.6%) with
endoscopy and the remaining 23 (10.5%) with both. There
were no differences in the pathological stage of the tumour
between the cases screened within a year and those screened
in the period of 1-2 years before in both SGC and AGC.
Comparisons of the pathological stage according to the
screening interval were done between three groups (A, cases
screened within 2 years; B, screened between 2 and 5 years
earlier; and C, screened more than 5 years earlier or not
screened) in both AGC and SGC cases (Table III). The cases
that dropped out from screening were included in group C.
As for the SGC cases, there were significant differences in the
pathological stages between groups A and C (P<0.0001) and
between groups B and C (P<0.05). There was also a
significant difference in the incidence of stage I tumours
between groups A and B (P<0.05). In the AGC cases, there
were differences in the incidence of group I tumours between
groups A and C (P<0.001) and between B and C (P<0.05).
This difference was not significant between groups A and B,
probably because of the small sample sizes. Interestingly,
there were also evident differences in the disease stages
between the previously screened SGC and AGC in the similar
screening interval groups.
In the 48 cases ofAGC detected in advanced stages (stages
III or IV), only nine cases had undergone gastric screening
test within a year. In other words, 39 cases with these
advanced AGC had demonstrated the gastric tumour at their
initial screening or at that with an interval of at least 1 year.
A surgical curative resection was accomplished on 407
(97.1%) cases of AGC. Six of them died within the first 30
post-operative days and 11 patients were lost to the follow-up.
In the following 390 patients, only 13 (3.3%) died of recurrent
disease and three ofthem died more than 5 years after primary
gastrectomy. Seventeen patients died of other (non-gastric)
malignancies, while 19 died ofeither non-neoplastic disease or
accidents. On the other hand, 1289 (74.6%) cases ofSGC were
curatively resected and 1171 of them were followed up. In
these cases, 220 (18.8%) cases died of recurrence and 26 of
them died more than 5 years after surgery. Twenty-seven died
of other malignancy and 180 died of either non-neoplastic
diseases or accidents. The cumulative 5 and 10 year survival
rates for patients with curatively resected AGC were 85.2%
and 72.2%, respectively, while those for patients with SGC
were 66.8% and 55.4% (Figure 1).
Discussion
We consider the Japanese superiority regarding the results of
gastric cancer treatment compared with western countries to
be attributable to the high incidence of early gastric cancer
and to the adoption of radical surgery with lymphadenect-
omy (Asao, 1990; Okamura et al., 1988; Wanebo et al., 1993).
As for the type of surgical intervention, the effect of extended
lymph node dissection on survival remains somewhat
controversial, especially in western countries (Dent et al.,
1988; Robertson, 1994). In Japan, a randomised study
comparing conservative with more radical surgery is difficult
to perform, because radical surgery is the gold standard for
gastric cancer, except for patients with severe systemic
1
c,o
0 5 10
Years after gastrectomy
Figure 1 The survival curves for curatively resected asympto-
matic gastric cancer (A, n =407) and symptomatic gastric cancer
(B, n = 1289). A statistically significant difference was observed in
the survival rate (P<0.01).
Table III Correlations between screening interval and pathological stage of the disease (%)
Screening interval No. of cases Stage I Stage II Stage III Stage IV
SGC
Group A 320 (18.5) 178 (55.6) 22 (6.9) 67 (20.9) 53 (16.6)
(within 2 years)
Group B 120 (6.9) 52 (43.3) 10 (8.3) 28 (23.3) 30 (25.0)
(2-5 years)
Group C 1287 (74.5) 395 (30.7) 121 (9.4) 384 (29.8) 387 (30.1)
(more than 5 years
or not screened)
AGC
Group A 188 (44.9) 165 (87.2) 10 (5.3) 10 (5.3) 3 (1.6)
Group B 32 (7.6) 24 (75.0) 1 (3.1) 6 (18.8) 1 (3.1)
Group C 199 (47.5) 147 (73.9) 24 (12.1) 23 (11.6) 5 (2.5)Asymptomatic gastric cancer
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complications or rather small early cancer, which is a good
candidate for conservative surgery. Early detection is
unquestionably effective for improving survival (Green et
al., 1988). The high incidence of gastric cancer in Japan has
led to the introduction and pervasion of gastric screening and
has resulted in a vigorous detection programme for gastric
cancer, involving both a double-contrast barium meal study
and endoscopy (Kampschoer et al., 1989).
The ultimate purpose of cancer screening is the detection
of preclinical lesions (Yamazaki et al., 1989; Hisamichi and
Sugawara, 1984) and, thus, asymptomatic gastric cancer is
the goal of gastric cancer screening. This current study
disclosed an excellent prognosis of AGC. Nearly half of all
cases were detected in the period of mucosal cancer, most of
the cases could be resected curatively and more than 85% of
them survived over 5 years.
The optimum screening interval for detecting gastric
cancer in the asymptomatic period is another problem.
Shiratori et al. (1985) recommended an interval of 1.5 years
of screening as being beneficial in detecting early gastric
cancer. The growth rate of gastric cancer, however, is not
uniform and some of them are known to show extremely
rapid growth and seldom to be detected at an early stage,
which thus undermines the usefulness of screening (Kodama
et al., 1984; Mori and Sugimachi, 1990, Nishidoi et al., 1992).
On the other hand, cases persisting in the mucosa for several
years have also been reported (Adachi et al., 1990). In this
study, there were evident differences in the tumour stages
between SGC and AGC, in spite of a similar screening
interval. We thus consider that some SGC grow more rapidly
than AGC.
In the AGC cases, 48 cases were detected for a gastric
tumour at stages III or IV, however, there were only nine
cases detected at these advanced stages in spite of periodic
annual screening. Furthermore, diffusely infiltrative cancer,
including scirrhous cancer, which is known to be a rapidly
growing and highly malignant tumour, was rarely found
among our asymptomatic cases. This type of tumour is thus
thought to develop within a few months and then rapidly
progress, and annual screening alone is thus insufficient to
detect it in its early phase of development (Haruma et al.,
1992).
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